UBS Group
BLSM

UBS Group’s BlossomHill Therapeutics BLSM Stock Holding History

UBS Group’s Portfolio BLSM Stock Details BLSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18.6K Buy
+997
New +$19.8K ﹤0.01% 8558

Other funds holding BLSM

JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Monashee Investment Management
Monashee Investment Management Boston, Massachusetts $33.4M AUM 92.4% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Aster Capital Management
Aster Capital Management Dubai, United Arab Emirates $275M AUM 18.46% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

UBS Group's BLSM Position: Q3 2026 in Review

UBS Group opened a new position in BlossomHill Therapeutics (BLSM) in Q3 2026: 997 shares worth $18.6K. The stake represents ﹤0.01% of the portfolio and ranks #8558 among its holdings.

11 funds tracked by Wall St. Rank hold BLSM as of Q3 2026.

  • UBS Group held 997 shares of BlossomHill Therapeutics worth $18.6K as of Q3 2026.
  • BlossomHill Therapeutics was a new UBS Group position in Q3 2026.
  • BlossomHill Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #8558 holding.
  • 11 funds tracked by Wall St. Rank held BlossomHill Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.